The COVID-19 vaccine co-developed by the American pharmaceutical giant Pfizer and the German biotechnology company BioNTech can neutralise variants of the novel corona virus that were first reported in the UK and South Africa, a new study suggests.
The research, published in the journal Nature Medicine, noted that the vaccine is effective against corona virus variants carrying the N501Y and E484K mutations.
According to the scientists, including those from the University of Texas in the US, these variants have a substitution of the amino acid building blocks that make up the viral spike protein the part of the virus which enables it to enter human cells.
They said these mutations in the 501st and 48th positions of the protein’s amino acid modules chain appeared in the UK and the South African variants, and could potentially increase the affinity of the viral spike for the receptor on the human cell through which the virus enters cells. In particular, they said the N501Y mutation may also expand the range of hosts the virus can infect to include mice.
In the current study, the scientists, Pel Yong Shi, and his colleagues engineered combinations of mutations found in these circulating variants and tested a panel of human sera from 20 participants. They said the sera were obtained from their clinical trial of the Pfizer-BioNTech vaccine obtained two or four weeks after immunisation with two doses spaced three weeks apart.
When they tested the serum against the corona virus strains, the authors found evidence of neutralisation of the mutant viruses by the sera panel, with slight variation. According to the scientists, neutralisation against the E484K mutation was slightly lower than that against the N501Y mutation.
Commenting on the research, virologist Lawrence young from the University of Warwick in the UK said the findings confirm previous studies indicating that the Pfizer vaccine is very likely to be effective against the UK variant.
Jonathan Ball, Professor of Molecular Virology, the University of Nottingham in the UK, also noted that the findings are promising.
Due to the ongoing evolution of the corona virus, the study authors called for continuous monitoring of vaccine efficacy for emerging variants.